Neogen’s Turnaround Metrics Improve; the 10/5 Long Still Does Not Clear 2026-10 / week-1 TRMD’s Final Seller Block Adds Supply, Not a Bounded Short 2026-10 / week-1 CEG’s Google agreement adds 890 MW, but not a per-share return bridge 2026-10 / week-1 APOG’s Earnings Rally Does Not Yet Support a Bounded Short 2026-10 / week-1 Option Care’s $32.05 deal leaves no 10/5 long after the gap 2026-10 / week-1 RPM’s CPG Weakness Is Real, but It Does Not Make a Bounded Short 2026-10 / week-1 Leidos keeps a 41.5% JV stake; value to LDOS shareholders remains undisclosed 2026-10 / week-1 SPHR’s Oz Downgrade Drop Does Not Bound a Short 2026-10 / week-1 Vaxcyte’s OPUS-1 win clears a clinical hurdle, not the price of the next phase 2026-10 / week-1 CHRW’s RXO Terms Raise the Capital Bill, Not a Bounded Short 2026-10 / week-1 PTC’s fixed $205 offer leaves too little upside for a long 2026-10 / week-1 SAFX’s Merger Vote Does Not Yet Bound the Share-Supply Risk 2026-10 / week-1 DRCT’s Nasdaq Suspension Is Not a Bounded Short 2026-10 / week-1 Penguin’s AI guide is strong; the October report still cannot underwrite a long 2026-10 / week-1 Celcuity has a launch, not yet a revenue bridge 2026-10 / week-1 ITOC’s Reverse Split Changes the Quote, Not the Short’s Risk Boundary 2026-10 / week-1 JAGX’s Series R Dividend Adds a Shareholder Clock, Not a Bounded Short 2026-10 / week-1 Leslie’s Plan Prices Out Existing Equity, but Suspension Is Not a Short Edge 2026-10 / week-1 Rivian's record deliveries do not yet clear a long hurdle 2026-10 / week-1 XELB’s Nasdaq Cure Window Does Not Create a Short Edge 2026-10 / week-1 PYXS’s $282.6M Headline Is Not $282.6M of Cash 2026-10 / week-1 Qorvo's Closing Spread Is Not a Long Opportunity 2026-10 / week-1 Edwards’ pediatric valve approval is not yet a 10/5 sales bridge 2026-10 / week-1 BNBX’s Pivot Is Announced; the Common Claim Is Still Unpriced 2026-10 / week-1 Equifax’s Bi-Merge Risk Is Real; the Short Is Not Yet Bounded 2026-10 / week-1 CareTrust’s £1.1B SHOP pipeline is not yet a 10/5 per-share return 2026-10 / week-1 IART’s Guide Cut Meets a Proposed Refi, but the Short Still Fails 10/5 2026-10 / week-1 Weak Payrolls Ease Yields; Long-Bond Supply Still Does Not Make TLT a 10/5 Short 2026-10 / week-1 MiniMed’s capped exchange ratio narrows the offer premium, but not the short’s squeeze risk 2026-10 / week-1 Synaptics Prices $123 Deal Certainty; the Remaining Spread Is Only 1.2% 2026-10 / week-1 VERI’s $0.75 Raise Narrows the Cash Gap, Not the Short’s Squeeze Risk 2026-10 / week-1 Synopsys’s Amazon Deal Is Signed; the 13% Repricing Still Lacks an Earnings Bridge 2026-10 / week-1 TLT’s Payroll Sensitivity Is Real; the Short Still Fails 10/5 2026-10 / week-1 Nike’s Revenue Miss Is Real; the Short Still Fails 10/5 2026-10 / week-1 NFG’s Ohio Utility Closed, but the Guide Still Fails 10/5 2026-10 / week-1 PUSA’s Merger-Day Rally Meets a 55 Million Share Claim, but the Short Fails 10/5 2026-10 / week-1 Acuity’s Q4 EPS Beat Leaves ABL Margin Risk Unresolved 2026-10 / week-1 Accenture Beats Q4; FY27 Guide Still Does Not Clear a +10% Base 2026-10 / week-1 McCormick’s Organic Volume Is Thin, but the Earnings-Day Short Still Fails 10/5 2026-10 / week-1 Micron’s Customer Deposits Improve Visibility, Not 10/5 Asymmetry 2026-10 / week-1 